LabGenomics Co. Ltd (KQ:084650) — Market Cap & Net Worth
Market Cap & Net Worth: LabGenomics Co. Ltd (084650)
LabGenomics Co. Ltd (KQ:084650) has a market capitalization of $5.67 Million (₩8.37 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #28329 globally and #2013 in its home market, demonstrating a -24.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LabGenomics Co. Ltd's stock price ₩922.00 by its total outstanding shares 9076740 (9.08 Million). Review debt load of LabGenomics Co. Ltd to assess the company's total debt and financial obligations.
LabGenomics Co. Ltd Market Cap History: 2015 to 2026
LabGenomics Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $13.98 Million to $5.67 Million (-8.70% CAGR).
Index Memberships
LabGenomics Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.00% | #1113 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.00% | #1113 of 1384 |
Weight: LabGenomics Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
LabGenomics Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LabGenomics Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
LabGenomics Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $13.98 Million | $23.59 Billion | $1.63 Billion | 0.00x | 0.01x |
| 2016 | $10.19 Million | $24.06 Billion | $723.51 Million | 0.00x | 0.01x |
| 2017 | $10.19 Million | $24.81 Billion | -$3.44 Billion | 0.00x | N/A |
| 2018 | $6.11 Million | $27.54 Billion | -$3.97 Billion | 0.00x | N/A |
| 2019 | $5.05 Million | $33.18 Billion | $962.42 Million | 0.00x | 0.01x |
| 2020 | $18.51 Million | $119.48 Billion | $42.77 Billion | 0.00x | 0.00x |
| 2021 | $24.79 Million | $202.41 Billion | $83.85 Billion | 0.00x | 0.00x |
| 2022 | $19.38 Million | $144.77 Billion | $48.40 Billion | 0.00x | 0.00x |
| 2023 | $23.71 Million | $71.08 Billion | -$4.67 Billion | 0.00x | N/A |
| 2024 | $15.32 Million | $85.90 Billion | -$23.80 Billion | 0.00x | N/A |
Competitor Companies of 084650 by Market Capitalization
Companies near LabGenomics Co. Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to LabGenomics Co. Ltd by market ranking:
- Cannassure Therapeutics Ltd (TA:CSURE): Ranked #31094 globally with a market cap of $217.46K USD ( ILA81.11 Million ILA).
- Hanwha Corp. Pfd. Series 1 (KO:000885): Ranked #28320 globally with a market cap of $5.70 Million USD ( ₩8.41 Billion KRW).
- Novatti Group Ltd (AU:NOV): Ranked #28321 globally with a market cap of $5.70 Million USD ( AU$8.05 Million AUD).
- Vectus Biosystems Ltd (AU:VBS): Ranked #28330 globally with a market cap of $5.67 Million USD ( AU$8.01 Million AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #31094 | Cannassure Therapeutics Ltd | TA:CSURE | $217.46K | ILA659.70 |
| #28320 | Hanwha Corp. Pfd. Series 1 | KO:000885 | $5.70 Million | ₩42250.00 |
| #28321 | Novatti Group Ltd | AU:NOV | $5.70 Million | AU$0.01 |
| #28330 | Vectus Biosystems Ltd | AU:VBS | $5.67 Million | AU$0.15 |
LabGenomics Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, LabGenomics Co. Ltd's market cap moved from $13.98 Million to $ 5.67 Million, with a yearly change of -8.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩5.67 Million | -49.09% |
| 2025 | ₩11.14 Million | -27.27% |
| 2024 | ₩15.32 Million | -35.41% |
| 2023 | ₩23.71 Million | +22.38% |
| 2022 | ₩19.38 Million | -21.83% |
| 2021 | ₩24.79 Million | +33.91% |
| 2020 | ₩18.51 Million | +266.28% |
| 2019 | ₩5.05 Million | -17.31% |
| 2018 | ₩6.11 Million | -40.00% |
| 2017 | ₩10.19 Million | 0.00% |
| 2016 | ₩10.19 Million | -27.15% |
| 2015 | ₩13.98 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of LabGenomics Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.67 Million USD |
| MoneyControl | $5.67 Million USD |
| MarketWatch | $5.67 Million USD |
| marketcap.company | $5.67 Million USD |
| Reuters | $5.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LabGenomics Co. Ltd
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.